Top

International Journal of Clinical Oncology

Published in:

01-06-2019 | Gastric Cancer | Review Article

Efficacy and safety of oxaliplatin-based regimen versus cisplatin-based regimen in the treatment of gastric cancer: a meta-analysis of randomized controlled trials

Authors: Gongchen Wang, Binfeng Yang, Zhaoyuan Fu, Xin Wang, Zhiming Zhang

Published in: International Journal of Clinical Oncology | Issue 6/2019

Abstract

Background

Cisplatin played an important role in the treatment of gastric cancer (GC). Oxaliplatin has been shown to be at least as effective as cisplatin for GC, with less toxicity and a better tolerability profile. We performed a meta-analysis to compare the efficacy and safety of oxaliplatin-based regimen versus cisplatin-based regimen in the treatment of GC.

Methods

Databases of CNKI, CBM, VIP, Wanfang, PubMed, Embase, Cochrane Library were searched for eligible literatures from their establishments to November 2018. Randomized controlled trials that compared the efficacy and safety of oxaliplatin-based regimen with that of cisplatin-based regimen in the treatment of GC were included. Statistical analyses were calculated using RevMan 5.3 software.

Results

Seven randomized controlled trials including 2297 patients were included. Compared with cisplatin-based regimen intervention in GC, oxaliplatin-based regimen treatment was able to significantly improve the partial response rate (OR = 1.26, 95% CI 1.07–1.49; p = 0.007), disease progression rate (OR = 0.41, 95% CI 0.25–0.66; p = 0.0002) and 1-year survival (OR = 1.25, 95% CI 1.00–1.56; p = 0.05). The toxicities of hematopoietic system were significantly higher in cisplatin-based regimen group (OR = 0.6, 95% CI 0.46–0.79; p = 0.0002), while oxaliplatin-based regimen group had higher neurosensory toxicity (OR = 2.21, 95% CI 1.52–3.21; p < 0.0001), In addition, gastrointestinal toxicity was similar between the two groups (OR = 1.01, 95% CI 0.5–2.01; p = 0.27).

Conclusions

Compared with cisplatin-based regimen, oxaliplatin-based regimen treatment has an obvious advantage in patients with GC with acceptable tolerance.

Ferlay J, Shin HR, Bray F et al (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127(12):2893–2917. https://doi.org/10.1002/ijc.25516 CrossRefPubMed

Jemal A, Center MM, DeSantis C et al (2010) Global patterns of cancer incidence and mortality rates and trends. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 19(8):1893–1907. https://doi.org/10.1158/1055-9965.epi-10-0437

Hartgrink HH, Jansen EP, van Grieken NC et al (2009) Gastric cancer. Lancet 374(9688):477–490. https://doi.org/10.1016/s0140-6736(09)60617-6 CrossRefPubMedPubMedCentral

Wilke H, Preusser P, Fink U et al (1989) Preoperative chemotherapy in locally advanced and nonresectable gastric cancer: a phase II study with etoposide, doxorubicin, and cisplatin. J Clin Oncol 7(9):1318–1326. https://doi.org/10.1200/jco.1989.7.9.1318 CrossRefPubMed

Bang YJ, Kim YW, Yang HK et al (2012) Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 379(9813):315–321. https://doi.org/10.1016/s0140-6736(11)61873-4 CrossRefPubMed

Paoletti X, Oba K, Burzykowski T et al (2010) Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA 303(17):1729–1737. https://doi.org/10.1001/jama.2010.534 CrossRefPubMed

Glimelius B, Ekstrom K, Hoffman K et al (1997) Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 8(2):163–168CrossRefPubMed

Yasui H, Tsurita G, Imai K (2014) DNA synthesis inhibitors for the treatment of gastrointestinal cancer. Expert Opin Pharmacotherap 15(16):2361–2372. https://doi.org/10.1517/14656566.2014.958074 CrossRef

Koizumi W, Narahara H, Hara T et al (2008) S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9(3):215–221. https://doi.org/10.1016/s1470-2045(08)70035-4 CrossRefPubMed

10.

Popov I, Radosevic-Jelic L, Jezdic S et al (2008) Biweekly oxaliplatin, fluorouracil and leucovorin versus cisplatin, fluorouracil and leucovorin in patients with advanced gastric cancer. J BUON 13(4):505–511PubMed

11.

Yamada Y, Higuchi K, Nishikawa K et al (2015) Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naive patients with advanced gastric cancer. Ann Oncol 26(1):141–148. https://doi.org/10.1093/annonc/mdu472 CrossRefPubMed

12.

Furlan AD, Pennick V, Bombardier C, et al (2009) 2009 updated method guidelines for systematic reviews in the Cochrane Back Review Group. Spine 34(18):1929–1941. https://doi.org/10.1097/BRS.0b013e3181b1c99f CrossRefPubMed

13.

Trotti A, Colevas AD, Setser A et al (2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13(3):176–181. https://doi.org/10.1016/s1053-4296(03)00031-6 CrossRefPubMed

14.

Lefebvre C, Glanville J, Wieland LS et al (2013) Methodological developments in searching for studies for systematic reviews: past, present and future? Syst Rev 2:78. https://doi.org/10.1186/2046-4053-2-78 CrossRefPubMedPubMedCentral

15.

Kim YS, Sym SJ, Park SH et al (2014) A randomized phase II study of weekly docetaxel/cisplatin versus weekly docetaxel/oxaliplatin as first-line therapy for patients with advanced gastric cancer. Cancer Chemother Pharmacol 73(1):163–169. https://doi.org/10.1007/s00280-013-2334-3 CrossRefPubMed

16.

Al-Batran SE, Hartmann JT, Probst S et al (2008) Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 26(9):1435–1442. https://doi.org/10.1200/jco.2007.13.9378 CrossRefPubMed

17.

Cunningham DSN, Rao S, Iveson T et al (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. New Engl J Med 358(18):36–46. https://doi.org/10.1056/NEJMoa073149 CrossRefPubMed

18.

Jianqun L, Yungen Z (2014) clinical study of oxaliplatin combined with 5-fluorouracil and calcium folinate for chemotherapy in patients with advanced gastric cancer. Clin Med Eng 21(11):1447–1448

19.

Wenyi W, yang X (2008) Clinical observation of cisplatin, oxaliplatin and paclitaxel in the treatment of advanced gastric cancer. Chin J Coal Ind Med 11(11):1726–1727

20.

Machover D, Diaz-Rubio E, de Gramont A et al (1996) Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann oncol 7(1):95–98CrossRefPubMed

21.

Kouroussis C, Souglakos J, Kakolyris S et al (2001) Oxaliplatin in combination with infusional 5-fluorouracil and leucovorin every 2 weeks as first-line treatment in patients with advanced colorectal cancer: a phase II study. Oncology 61(1):36–41. https://doi.org/10.1159/000055350 CrossRefPubMed

22.

Land SR, Kopec JA, Cecchini RS et al (2007) Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. J Clin Oncol 25(16):2205–2211. https://doi.org/10.1200/jco.2006.08.6652 CrossRefPubMed

23.

Argyriou AA, Polychronopoulos P, Iconomou G et al (2008) A review on oxaliplatin-induced peripheral nerve damage. Cancer Treat Rev 34(4):368–377. https://doi.org/10.1016/j.ctrv.2008.01.003 CrossRefPubMed

24.

Andre T, Boni C, Mounedji-Boudiaf L et al (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. New Engl J Med 350(23):2343–2351. https://doi.org/10.1056/NEJMoa032709 CrossRefPubMed

25.

Tournigand C, Cervantes A, Figer A et al (2006) OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer—a GERCOR study. J Clin Oncol 24(3):394–400. https://doi.org/10.1200/jco.2005.03.0106 CrossRefPubMed

26.

Cascinu S, Catalano V, Cordella L et al (2002) Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 20(16):3478–3483. https://doi.org/10.1200/jco.2002.07.061 CrossRefPubMed

27.

Gamelin L, Boisdron-Celle M, Delva R et al (2004) Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res 10(12 Pt 1):4055–4061. https://doi.org/10.1158/1078-0432.ccr-03-0666 CrossRefPubMed

28.

Nagamatsu M, Nickander KK, Schmelzer JD et al (1995) Lipoic acid improves nerve blood flow, reduces oxidative stress, and improves distal nerve conduction in experimental diabetic neuropathy. Diabetes Care 18(8):1160–1167CrossRefPubMed

29.

Nickander KK, McPhee BR, Low PA et al (1996) Alpha-lipoic acid: antioxidant potency against lipid peroxidation of neural tissues in vitro and implications for diabetic neuropathy. Free Radic Biol Med 21(5):631–639CrossRefPubMed

30.

Gedlicka C, Scheithauer W, Schull B et al (2002) Effective treatment of oxaliplatin-induced cumulative polyneuropathy with alpha-lipoic acid. J Clin Oncol 20(15):3359–3361. https://doi.org/10.1200/jco.2002.99.502 CrossRefPubMed

Title: Efficacy and safety of oxaliplatin-based regimen versus cisplatin-based regimen in the treatment of gastric cancer: a meta-analysis of randomized controlled trials
Authors: Gongchen Wang
Binfeng Yang
Zhaoyuan Fu
Xin Wang
Zhiming Zhang
Publication date: 01-06-2019
Publisher: Springer Singapore
Keywords: Gastric Cancer
Gastric Cancer
Cytostatic Therapy
Published in: International Journal of Clinical Oncology / Issue 6/2019
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-019-01425-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2019

Radiotherapy alone as a possible de-intensified treatment for human papillomavirus-related locally advanced oropharyngeal squamous cell carcinoma

Saddle pulmonary embolism and in-hospital mortality in patients with cancer

CT and clinical characteristics that predict risk of EGFR mutation in non-small cell lung cancer: a systematic review and meta-analysis

Cryosurgery for primary breast cancers, its biological impact, and clinical outcomes

Resection of pancreatic metastatic renal cell carcinoma: experience and long-term survival outcome from a large center in China

Squamous cell carcinoma of the bladder: poor response to neoadjuvant chemotherapy

Keynote webinar | Spotlight on antibody–drug conjugates in cancer